Currently Viewing
FDA Approves Inrebic to Treat Myelofibrosis
August 16, 2019 – Kristie L. Kahl
FDA Approves Rozlytrek to Treat Certain Patients With an NTRK Gene Fusion and NSCLC
August 15, 2019 – Katie Kosko
How Do You Overcome the Fear That Comes With Cancer?
August 15, 2019 – Jessica Skarzynski
Side Issues: Addressing the Effects of Gastrointestinal Cancers
August 15, 2019 – Meeri N. Kim, Ph.D.
Heal New Issue Alert: Spring 2019
August 14, 2019 – Katie Kosko and Brielle Benyon
Study Unveils Family Risk for Certain Types of Blood Cancer
August 14, 2019 – Kristie L. Kahl
Summer Snacktime: Strawberry, Basil and Ricotta Toast Recipe
August 14, 2019 – Jessica Skarzynski
Cancer Support Groups Aid in Developmental Process of a Cancer Diagnosis
August 13, 2019 – Kristie L. Kahl
Study Asks: Are Women Missing Out on BRCA Testing?
August 13, 2019 – Meredith Begley and Julie Grisham

FDA Approves Inrebic to Treat Myelofibrosis

The Food and Drug Administration approved Inrebic as the first new treatment in nearly a decade for patients with myelofibrosis.
 
BY Kristie L. Kahl
PUBLISHED August 16, 2019
The Food and Drug Administration (FDA) approved Inrebic (fedratinib) as the first new treatment in nearly a decade for patients with myelofibrosis, according to Celgene – the agent’s manufacturer.

“Myelofibrosis can cause patients to suffer in many ways, including experiencing debilitating symptoms,” Dr. Ruben Mesa, director of the Mays Cancer Center at UT Health San Antonio Cancer Center MD Anderson, said in a press release. “There has not been a new treatment approved for this disease in nearly a decade. With Inrebic, physicians and patients now have another option available for myelofibrosis.”

Myelofibrosis is a serious and rare bone marrow disorder that disrupts the body’s normal production of blood cells, which can lead to anemia, weakness, fatigue and enlargement of the spleen and liver, among other symptoms.

The agency approved the JAK-2 inhibitor for treatment in patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis based on findings from the JAKARTA trial.

The study demonstrated that patients experienced a 35% or great spleen volume reduction. Serious side effects included cardiac failure (5%) and anemia (2%).

Check back later for more information on what this approval means for patients.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the MPN CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In